1-Acetyl-4-phenyl-4-piperidinol | 71388-47-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Acetyl-4-phenyl-4-piperidinol
• 英文别名: 4-Phenyl-1-acetyl-4-piperidinol；1-acetyl-4-phenyl-piperidin-4-ol；1-acetyl-4-hydroxy-4-phenylpiperidine；1-(4-hydroxy-4-phenylpiperidin-1-yl)ethanone
• CAS: 71388-47-1
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: WGQQPDXFAMGTPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Acetyl-4-phenyl-4-piperidinol 以97%的产率得到
  参考文献：
  名称：

  MARTIN L. L.; KLIOZE S. S.; WARM M.; CRICHLOW C. A.; GEYER H. M.; KRUSE H+, J. MED. CHEM., 1979, 22, NO 11, 1347-1354

  摘要：

  DOI：
• 作为产物：
  描述：

  4-苯基-4-羟基哌啶 、 乙酸酐 以89%的产率得到
  参考文献：
  名称：

  MARTIN L. L.; KLIOZE S. S.; WARM M.; CRICHLOW C. A.; GEYER H. M.; KRUSE H+, J. MED. CHEM., 1979, 22, NO 11, 1347-1354

  摘要：

  DOI：

文献信息

• Structure–activity relationship of trihexyphenidyl analogs with respect to the dopamine transporter in the on going search for a cocaine inhibitor
  作者：D.E. Dar、M. Thiruvazhi、P. Abraham、S. Kitayama、T.A. Kopajtic、A. Gamliel、B.S. Slusher、F.I. Carroll、G.R. Uhl

  DOI：10.1016/j.ejmech.2005.04.016

  日期：2005.10

  a derivative that could serve as a cocaine inhibitor. A compound that blocks binding of the cocaine analog carboxyfluorotropane (CFT), allows dopamine uptake and exhibits low side effects could serve as a good candidate for that purpose. All analogs were tested for the extent to which they inhibit CFT binding, dopamine uptake and n-methyl scopolamine (NMS) binding. Several structure-function relationships

  一系列的三己基苯基（THP）类似物用于寻找可以用作可卡因抑制剂的衍生物。阻止可卡因类似物羧基氟代烷（CFT）结合，允许多巴胺摄取并表现出低副作用的化合物可以用作该目的的良好候选者。测试了所有类似物抑制CFT结合，多巴胺摄取和正甲基东pol碱（NMS）结合的程度。出现了几种结构功能关系。与THP苯环的甲基化/卤化相比，该化合物阻断CFT结合的能力与其阻断多巴胺摄取的能力相比有所提高（5a-e）。用苯环取代环己基环往往会产生对多巴胺转运蛋白的亲和力较低的化合物（7b相比THP，7d相比5h，7c与8c相比）和THP哌啶环的修饰倾向于增强与多巴胺转运蛋白的亲和力（5f-h，8a，8c）。研究了一种几乎没有毒蕈碱活性的类似物（5f），这表明它可能具有很少的副作用，作为其体内可卡因抑制剂的作用已得到研究。但是，它在体内几乎没有拮抗作用。然而，这项工作极大地阐明了潜在可卡因抑制剂所需的结构-功能关系，
• Nitrogen-containing heterocyclic compound and use thereof
  申请人：Ikeura Yoshinori

  公开号：US20090156572A1

  公开（公告）日：2009-06-18

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R 2 is an optionally halogenated C 1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.

  本发明涉及一种由下式表示的化合物：其中环A是含氮杂环，可选择地进一步具有取代基，环B是芳香环，可选择地具有取代基，环C是环状基团，可选择地具有取代基，R1是氢原子，一个碳氢基团，可选择地具有取代基，酰基，一个杂环基团，可选择地具有取代基或一个氨基团，可选择地具有取代基，R2是可选择卤代的C1-6烷基基团，m和n分别是0到5的整数，m+n是2到5的整数，是单键或双键，或其盐等。由于该化合物具有优越的催吐肽受体拮抗作用，可用作预防或治疗多种疾病的药物，如下尿道疾病、胃肠道疾病、中枢神经系统疾病等。
• 1-carbonyl derivatives of 4-aryl-4-aryloxypiperidines
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04853384A1

  公开（公告）日：1989-08-01

  1-Carbonyl derivatives of 4-aryl-4-aryloxypiperidines and methods for alleviating pain and treating convulsions utilizing compounds or compositions thereof are disclosed.

  揭示了4-芳基-4-芳氧基哌啶的羰基衍生物以及利用其化合物或组合物缓解疼痛和治疗惊厥的方法。
• Hsp90 FAMILY PROTEIN INHIBITORS
  申请人：Nara Shinji

  公开号：US20090247522A1

  公开（公告）日：2009-10-01

  The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

  本发明提供了Hsp90家族蛋白抑制剂，其包含作为活性成分的苯甲酰化合物，其通式表示为（I）：（其中n表示0到10的整数；R1表示取代或未取代的低烷氧基，取代或未取代的低烷氧羰基，CONR7R8或类似物；R2表示取代或未取代的芳基，取代或未取代的芳香杂环基或类似物；R3和R5，可以相同也可以不同，分别表示氢原子，取代或未取代的低烷基，取代或未取代的低烯基或类似物；R4和R6，可以相同也可以不同，分别表示氢原子，卤素，取代或未取代的低烷基，取代或未取代的芳基或类似物）或其前药，或其药学上可接受的盐。
• Hsp90 family protein inhibitors
  申请人：Nara Shinji

  公开号：US20070032532A1

  公开（公告）日：2007-02-08

  The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R 1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR 7 R 8 or the like; R 2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R 3 and R 5 , which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R 4 and R 6 , which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

  本发明提供了Hsp90家族蛋白抑制剂，其作为活性成分包括由通式（I）表示的苯甲酰化合物： （其中，n代表0至10的整数；R1代表取代或未取代的较低烷氧基、取代或未取代的较低烷氧羰基、CONR7R8等；R2代表取代或未取代的芳基、取代或未取代的芳香族杂环基等；R3和R5，可以相同也可以不同，每个代表氢原子、取代或未取代的较低烷基、取代或未取代的较低烯基等；R4和R6，可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基、取代或未取代的芳基等）或其前药，或所述苯甲酰化合物或其前药的药学上可接受的盐。